Home / Health / New Jab Outperforms Mounjaro in Weight Loss
New Jab Outperforms Mounjaro in Weight Loss
1 Sep
Summary
- Retatrutide helped patients lose 22.1% of body weight.
- New study compared weight loss drugs and their effects.
- Gastrointestinal side effects were common but mild.
An experimental weight-loss jab, retatrutide, has shown promising results, potentially surpassing the effectiveness of Mounjaro. Research indicates retatrutide aided patients in losing approximately 22.1% of their body weight within 48 weeks. This finding emerged from an analysis of 38 trials involving over 25,000 participants, published in the Annals of Internal Medicine.
The study compared various weight-loss treatments, including tirzepatide (the active ingredient in Mounjaro), which resulted in patients losing about 19% of their body weight. Other experimental medicines like amycretin and Foundayo also demonstrated significant weight reduction percentages.
Weight-loss injections, known as GLP-1 receptor agonists, function by mimicking natural hormones that control blood sugar, appetite, and digestion. Retatrutide uniquely targets three hormone pathways: GLP-1, GIP, and glucagon, thereby reducing food intake and increasing energy expenditure.
While participants experienced gastrointestinal side effects, serious adverse events were rare, suggesting a favorable safety profile for these therapies. The findings support GLP-1-based treatments as effective options for weight management.
